Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
MultiMetaVerse Plans to Acquire Equity Stake in Taomee June 2, 2023
Janssen to Move forward with Clinical Development of LAVA Therapeutics’s Lead Gamma-Delta T-Cell Engager Bispecific Antibody June 2, 2023
Autolus Therapeutics to Present Positive Results from its Phase 2 FELIX study in adult r/r B-ALL at ASCO June 2, 2023
Connect Biopharma Higher on Positive Phase 2 Icanbelimod Trial Data June 2, 2023
Monopar Reports Positive Camsirubicin Phase 1b Trial Update June 1, 2023
Next
Prev

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

  • May 5, 2022 at 6:06 AM

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today will share preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2022, being held in San Francisco, CA, May 4-7, 2022 on GDA-301 and GDA-601, two product candidates in the Company’s NAM-enabled genetically modified natural killer (NK) pipeline. “The preclinical data gen

Read the entire article here.

RelatedNews

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.